A Case of Severe, Nilotinib-Induced Liver Injury

Idiosyncratic hepatotoxicity is a leading reason for the discontinuation or dose modification of Food and Drug Administration (FDA)-approved medications in the United States. We report the case of a 53-year-old woman with chronic myeloid leukemia who developed acute cholestatic hepatitis in response...

Descripción completa

Detalles Bibliográficos
Autores principales: Belopolsky, Yuliya, Grinblatt, David L., Dunnenberger, Henry M., Sabatini, Linda M., Joseph, Nora E., Fimmel, Claus J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657995/
https://www.ncbi.nlm.nih.gov/pubmed/31616712
http://dx.doi.org/10.14309/crj.0000000000000003
Descripción
Sumario:Idiosyncratic hepatotoxicity is a leading reason for the discontinuation or dose modification of Food and Drug Administration (FDA)-approved medications in the United States. We report the case of a 53-year-old woman with chronic myeloid leukemia who developed acute cholestatic hepatitis in response to the tyrosine kinase inhibitor nilotinib. Nilotinib was discontinued, and the patient's liver function tests normalized over the next 3 months. We conclude that nilotinib may cause life-threatening hepatotoxicity and recommend that patients on the medication undergo regular monitoring of their liver tests.

Ejemplares similares